THREE-MONTH REPORT

JANUARY - MARCH 2013

- Net revenue amounted to SEK 4.4 million (6.8).
- The net loss totaled SEK 4.7 million (2.3), a deterioration of SEK 2.4 million due to the fall in revenue.
- Earnings per stock unit amounted to SEK -0.01 (-0.01).
- Artimplant prolongs its funding agreement regarding costs for trials in USA and recovers previous legal costs of SEK 5 million.
- Artimplant has requested arbitration in the insurance dispute.
- The Company is in need of a capital injection, the Board has therefore decided to review its strategic options.

EVENTS AFTER THE PERIOD-END

- The Company has entered into a sales, marketing and distribution agreement with Tiller International Capital. The agreement grants Tiller the exclusive right to sell, market and distribute all Artimplant's products outside Europe and a non-exclusive right within Europe.
- The Board postponed the Annual General Meeting until June 27, 2013.

** Figures in brackets refer to the corresponding period last year.*

N. B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant
Degradable Materials for Optimal Tissue Repair

ABOUT ARTIMPLANT

ARTIMPLANT is a medical technology company, where the focus is on innovative orthopedic solutions.

Artimplant helps to improve the patient's quality of life by offering the medical sector products that create conditions for the body to heal.

OPERATIONS are carried on through the Parent Company, Artimplant AB, and the Company's wholly owned subsidiary, Artimplant USA, Inc. The Parent Company's premises in Gothenburg house production, administration, clinical testing as well as the sales and marketing function. The US subsidiary is responsible for sales and marketing activities on the North American market through the office in Dallas, Texas.

Artimplant is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the Healthcare sector.

THE PRODUCTS are manufactured from the patented material Artelon®, developed by the Company and used to reinforce soft tissue and for the treatment of osteoarthritis. The first implants using Artelon® were carried out in 1997, which means that there is 15 years of clinical experience of the material.

Artelon® Tissue Reinforcement, ATR

Artelon® Tissue Reinforcement has a textile design that provides porosity, and which means that the new body tissue grows into the product and reinforces the repair in the long term. The unique elasticity of the product contributes to stimulating the body's cells to form new tissue with the same features as the damaged tissue. Through controlled degradation, it can be ensured that the reinforcing function remains for a sufficiently long period to allow the injury to heal.

Artelon® Tissue Reinforcement has been cleared for marketing in the USA and the EU.

Artelon® Spacer

Artimplant has developed the implant for patients with osteoarthritis in the thumb base joint or big toe joint. The damaged tissue is removed and replaced by an Artelon® implant and the body's own cells and can grow into and form new, shock-absorbing tissue. The anatomy is thus preserved, which offers good prerequisites for regaining a functional joint with reduced pain and retained strength, stability and movement.

The products for osteoarthritis in the thumb base joint have been cleared for marketing in the USA, Europe and the number of other countries. The product for osteoarthritis in the big toe joint has been cleared for marketing in Europe and is currently being evaluated in a number of selected countries.

> Artimplant's products function as scaffolding for the body cells and helps the body to heal.

STATEMENT BY THE CEO

An important step has been taken in the development of Artimplant with the signing of a co-operation agreement with Tiller International Capital. The agreement gives Artimplant access to Tiller's extensive healthcare network and offers substantial marketing opportunities for our products, particularly on the pivotal US market. During the coming weeks, a final sales and distribution agreement will be negotiated and the agreement that has now been signed should be seen as a general agreement outlining the parties' intentions.

Discussions with Tiller have been conducted in a positive spirit and it is my conviction that through this agreement we will establish a solid platform on which to build for the future. Artimplant has acquired the partner that it has needed for a long time. With established distribution channels and collaboration on several markets, entirely new conditions will be created to bring about good, effective communication with our users.

Both Tiller and we feel there is considerable potential for our products on the US market and on the other markets in which Tiller operates. "With our network in the healthcare systems and the partners we are cooperating with, we see huge potential in Artimplant's products and we are looking forward to a very fruitful future together," states Anthony N. Georgiou, Chairman of Tiller.

A great deal of work remains before the agreement in its entirety is in place. Nor should we believe that everything has been resolved through this agreement. A great deal of work still has to be done but the important thing is that we have created an excellent base from which we can now grow our operations.

Development during the first quarter of the year has not come up to our expectations. The downward trend in sales is continuing and we have not been able to compensate by reducing costs to the same extent.

As can be seen from our previous communications, and in particular from our financial development, the Company is in need of further capital input. There has been a clear focus on this area by the Board of Directors and the executive management and discussions are currently taking place with a number of potential stakeholders. However, it is still too early to express a final opinion although we expect to be able to present a proposal soon.

The complaints directed at Artimplant in the USA are continuing. At present, we have 53 complaints and the first court proceedings are scheduled for the end of the year. A great deal of time has been devoted to this and the related insurance disputes. To resolve the insurance situation in accordance with the agreements entered into, Artimplant has convened arbitration proceedings in order to reach a solution regarding allocation of claim costs between the insurance carriers and the insurance broker.

This has of course meant that the focus on day-to-day operations has suffered since the first quarter. The management team has devoted a great deal of time to finding solutions for the Company's future and related negotiations and discussions. Discussions about the Company's future funding are now entering the final phase and I hope to present some form of solution for the Company's future very shortly.

In presenting the grounds for the co-operation agreement with Tiller, the Board of Directors and I believe we have laid a firm foundation for the Company's future. It now remains to secure the requisite capital to build up a profitable unit in the long term.

Västra Frölunda, May 30, 2013

Kjell Thörnbring

THREE-MONTH REPORT

REVENUE AND FINANCIAL RESULTS JANUARY – MARCH

Revenue

Artimplant's net revenue for the year amounted to SEK 4.4 million (6.8) and was primarily revenue from product sales. In total, 77 percent (76) of revenue can be attributed to sales on the US market, amounting to SEK 3.4 million (5.2), and revenue attributable to the European market totaled SEK 1 million (1.6), equivalent to 23 percent (24) of total revenue.

The gross margin during the period January-March was 89 percent (89) and the gross result fell by SEK 2.1 million compared to the preceding period, totaling SEK 4.0 million (6.1).

SALES	Q1 2013		Q1 2012	
	KSEK	%	KSEK	%
USA	3,396	77	5,180	76
Europe	1,037	23	1,641	24
Other markets	-	-	-	-
Total	4,433	100	6,821	100

Operating result for the period

The operating loss increased by SEK 2.4 million and amounted to SEK 4.7 million (2.3) due mainly to a fall in revenue of SEK 2.4 million compared to the previous period. Administration costs increased by SEK 0.4 million due to the cost of complaints in the USA as the insurance premiums for the first quarter increased by SEK 0.3 million and legal costs increased by SEK 0.1 million compared to the previous period. The Company's research and development costs and sales costs are on the same level as the corresponding period last year.

Other costs refer mainly to exchange rate losses on operating liabilities and receivables.

Result after tax for the period

The result after tax for the period was SEK -4.7 million (-2.3). Earnings per stock unit totaled SEK -0.01 (-0.01).

Total income for the period

Total income for the period was SEK -4.6 million (-2.3). Total income includes the translation difference that arose in conjunction with translation of the US subsidiary into SEK.

SEASONAL EFFECTS

Artimplant has not been exposed to any material impact from seasonal effects in revenue or costs during the reporting period.

INVESTMENTS AND CASH POSITION

Cash and cash equivalents totaled SEK 8 million (24.5) at the period-end.

Cash flow was affected positively during the period by a repayment of SEK 4.6 million in respect of litigation costs that Artimplant has paid prior to the financing agreement. The agreement that was entered into during the period with the two insurance carriers and the insurance broker aims to cover Artimplant's litigation costs in the USA until a solution is reached in the current insurance dispute.

Cash flow was also affected negatively during the period to the amount of SEK 3.1 million due to prepaid insurance costs for the whole of 2013.

No investments were made in the Company during the period.

ORGANISATION AND PERSONNEL

At the period-end, Artimplant had 17 employees (17), of whom 8 (9) were women and 9 (8) were men. Four people are employed at Artimplant USA, Inc. The remainder are employed by Artimplant AB. In the USA, there are also three people working as consultants.

MARKET DEVELOPMENT

The market for orthopedic products is largest in the developed part of the world with Europe, the USA and Japan accounting for around 80 percent of the total market. The market is driven by a number of factors linked to demography and standard of living, where increasing welfare is a strong driving force for growth.

Since the middle of April 2012, sales in the USA have taken place entirely through agents. This is very common on the medical technology market in the USA. Artimplant delivers directly from its own inventory, bills the end-customer and pays sales-based commission to the 35 or so agents. The local distributor has an important role to play as sales are founded largely on relationships. This makes the recruitment of distributors extremely important and they are chosen with great care.

In Europe, there are country-specific distribution agreements and the distributor maintains its own inventory of products and bills the end-customer. The 20 or so European distributors are supported by the head office in Sweden. With effect from January 2012, sales will take place directly to customers in the Nordic region.

Sales during the first quarter of 2013

Sales in the US and Europe have not developed as expected.

The agreement with Tiller gives the Company good possibilities to turn the negative trend.

EVENTS AFTER THE END OF THE REPORTING PERIOD

Artimplant AB and Tiller International Capital have today entered into an agreement regarding a Sales, Marketing and Distribution Agreement which will gives Tiller the exclusive right to sell, market and distribute all Artimplant´s products outside Europe and non exclusively within Europe.

The detailed operational procedures are expected to be completed within the next four weeks.

The current sales efforts of Artimplant in the USA will be coordinated with Tiller to support both new and existing customers in the best way.

Tiller works extensively with Healthcare groups such as Catholic Healthcare on a Global basis to provide the best possible facilities and treatment for patients. Catholic Healthcare treats 30,000,000 patients a year in its more than 600 hospitals.

"I am very happy and satisfied to enter into this Agreement with Tiller. The Agreement gives Artimplant a good platform to expand the business and also a partner who has a lot of experience from both the US and Global markets", says Kjell Thörnbring, CEO Artimplant.

Anthony N. Georgiou, Chairman of Tiller says, "With our network in the Healthcare systems and the partners we are cooperating with, we see a huge potential in Artimplant´s products and are looking forward to a very fruitful future together".

In April, the Board of Directors decided to delay the Annual Meeting until June 27, 2013.

FUTURE PROSPECTS

It is difficult at present to assess the extent to which the complaints being handled by the Company in the USA will affect sales of the Company's products. Sales are increasing in both the USA and Europe and it is the firm belief of the executive management that there is a good market for the Company's products.

During the two years that discussions regarding financing of proceedings have been taking place with the two insurance carriers, day-to-day operations have suffered. Many of the members of the management team have been involved in finding solutions and several key decisions have been postponed pending a solution to the insurance issue. The cost of legal advice has increased significantly and insurance costs have risen to an entirely unrealistic level for the Company. Carrying on normal operations under these conditions is challenging.

The proceedings in the USA are continuing. The first cases will be the subject of a court hearing during late autumn/winter 2013/2014.

Artimplant stands by its belief that the outcome from the hearings will be positive for the Company.

In conjunction with the extension of the financing agreement in February, the insurance carriers and the insurance broker finally came to the realization that it was not possible to reach agreement on how the legal costs should be divided between the insurance companies and/or the insurance broker. The parties have therefore agreed that this should be resolved as quickly and efficiently as possible through arbitration. Artimplant therefore convened arbitration proceedings in this matter at the Arbitration Institute of the Stockholm Chamber of Commerce on February 25, 2013. It is Artimplant's opinion that there is satisfactory insurance cover. This opinion is also reinforced through the agreement that has now been signed whereby Artimplant has received compensation for its earlier litigation costs.

Due to the Company's weak development, the financial situation is under pressure. To ensure its survival, the Company is in need of further external financing of current operations. The weak sales trend has continued. How the sales trend has been affected by the current complaints and how it is assessed it will affect the Company in the future, as long as this process is not resolved, means that at present the Companies is unable to assess when the cash flow will be positive. Reducing the Company's cost mass to such a low level that the present sales volume will make the Company profitable is deemed unrealistic and consequently the Board of Directors has decided to review the Company's strategic alternatives. The Board of Directors and the President are working intensively to find solutions to the situation that has arisen and ways in which the Company can acquire financing in the short-term.

With the newly signed agreement with Tiller, the Company's assessment of the future is positive. The Tiller network offers the Company access to a large market with significant marketing opportunities for the Company's products.

SIGNIFICANT RISKS AND UNCERTAINTY FACTORS

The Company's significant risks and uncertainty factors are presented in the Board of Directors' Report in the most recent Annual Report, presented on the Company's website www.artimplant.com.

Since the fourth quarter of 2010, Artimplant and its former licensee Small Bone Innovations, Inc. have been the subject of complaints from patients in the USA. The amount of damages claimed has not yet been determined. Artimplant is contesting all allegations. Artimplant has filed a notice of loss with its insurance carrier and its assessment is that there is adequate insurance cover for any damages that may arise over and above the deductible. It is too early to assess if or when the court will hear all the cases and how long it could take for the cases to be resolved.

PARENT COMPANY

The majority of Artimplant's operations are run through the Parent Company, Artimplant AB. Artimplant USA, Inc. is the Company's only operating subsidiary. During the period, the Parent Company made an impairment of receivables from Artimplant USA, Inc. totaling SEK 1.2 million. Together with an earlier impairment of SEK 34.9 million in the opening balance, the total impairment is SEK 36.1 million.

ACCOUNTING PRINCIPLES

Artimplant applies IFRS. This interim report has been prepared in accordance with IAS 34, the Swedish Annual Accounts Act and RFR 1. The Parent Company's financial statements are prepared in accordance with exceptions and addenda in RFR 2. No new or amended IFRS that came into effect in 2012 or 2013 have had any significant impact on the Group. Further accounting principles can be found in the Company's Annual Report for 2012, which is available on the Company's website.

ANNUAL MEETING OF STOCKHOLDERS

The Artimplant AB Annual Meeting will be held on June 27, 2013, at 5 pm, at the Company offices at the address below. The premises will be open for registration at 4 pm. Artimplant AB Hulda Mellgrens gata 5, SE-421 32 Västra Frölunda, Sweden

Stockholders who wish to participate must comply with the following:

- Stockholders must register their participation with the Company no later than June 20, 2013 in one of the following ways:
  - By e-mail to agm2013@artimplant.com
  - By fax on +46 31-746 56 60
  - By telephone on +46 31-746 56 00
  - In writing to Artimplant AB, Annual Meeting 2013 Hulda Mellgrens gata 5, SE-421 32 Västra Frölunda, Sweden

  Notification should include details of name, civic registration number or company registration number, address, phone num¬ber and stockholding as recorded in the stockholders' register on June 20, 2013.

- Stockholders must be recorded in the stockholders' register maintained by Euroclear Sweden AB no later than June 20, 2013.

  To attend the meeting, stockholders whose stocks are recorded in the names of nominees through a bank or similar institution must request to have their holdings temporarily re-registered in their own names at Euroclear Sweden AB. Reregistration must be completed by June 20, 2013 at the latest.

Summons and other information about the Annual General Meeting is available on the Company's website, www.artimplant.com. The meeting will be held in Swedish and all related documents are presented in Swedish.

DIVIDEND

The Board of Directors has proposed that no dividend be paid for 2012.

UPCOMING INFORMATION

Annual Meeting	June 27, 2013
Six-month Report	August 14, 2013
Nine-month Report	November 20, 2013

Financial reports are published on the Company's website www.artimplant.com and are distributed to the media at the same time. For information regarding the business model, technology and products, reference can be made to the Artimplant Annual Report 2012, which is available on the Company's website.

For further information, please contact
Kjell Thörnbring, Chief Executive Officer
Tel + 46 31 746 56 46, +46 703 119 125
kjell.thornbring@artimplant.com

Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
Sweden

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com

Reg. No. 556404-8394
Reg. office Municipality of Gothenburg, County of Västra Götaland

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Amounts in KSEK	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
Net sales	4,433	6,821	21,067
Cost of goods and services sold	-480	-765	-2,248
Gross profit	3,953	6,056	18,819
Other income	-	-	601
Research and development costs	-1,437	-1,509	-7,237
Selling costs	-4,484	-4,439	-21,382
Administrative costs	-2,518	-2,149	-6,361
Other costs	-194	-243	-1,191
Operating loss	-4,680	-2,284	-16,751
Interest income and other financial income	40	35	369
Interest expense and other financial expense	-24	-44	-140
Net financial items	16	-9	229
Loss after financial items	-4,664	-2,293	-16,522
Tax	-	-	-
Loss for the period	-4,664	-2,293	-16,522
Exchange differences arising on translation of foreign operations	90	62	395
Total comprehensive loss for the period	-4,574	-2,232	-16,127
Loss attributable to the Parent Company's stockholders	-4,664	-2,293	-16,522
Earnings per stock unit, SEK	-0.01	-0.01	-0.03
Earnings per stock unit after dilution, SEK	-0.01	-0.01	-0.03

The statements include depreciations and amortization of tangible assets and intangible non-current assets as shown in the following table:

Amounts in KSEK	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
(1) Capitalized R&D costs	30	30	120
(2) Patents and brands	22	38	128
Sales rights	66	-	132
Machinery and equipment	9	22	89
Total depreciation	127	90	469

CONSOLIDATED ALLOCATION OF NET SALES

Amounts in KSEK	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
SOURCE OF REVENUE			
Product sales to end-customers and distributors	4,365	6,800	20,790
Contract product development and other sales	68	21	277
Total	4,433	6,821	21,067
GEOGRAPHIC AREAS			
North America	3,396	5,180	16,688
Europe	1,037	1,641	4,243
Other areas	-	-	136
Total	4,433	6,821	21,067

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Amounts in KSEK

ASSETS	3/31/2013	3/31/2012	12/31/2012
Capitalized product development costs	290	410	320
Patents and brand names	99	211	121
Sales rights	2,435	-	2,501
Total intangible non-current assets	2,824	621	2,942
Machinery and equipment	23	98	32
Total tangible non-current assets	23	98	32
Total non-current assets	2,847	719	2,974
Raw materials, semi-finished and finished goods	4,066	4,461	4,144
Total inventories etc.	4,066	4,461	4,144
Accounts receivable	3,212	4,379	3,377
Other receivables	14,504	4,584	12,758
Prepaid expenses and accrued income	3,801	3,579	1,905
Total current receivables	21,516	12,542	18,040
Cash and bank accounts	8,015	24,542	10,386
Total current assets	33,597	41,545	32,570
TOTAL ASSETS	36,444	42,264	35,544

STOCKHOLDERS' EQUITY & LIABILITIES	3/31/2013	3/31/2012	12/31/2012
Capital stock	10,280	10,280	10,280
Other capital reserves	74,361	74,358	74,361
Other contributed capital	-65,454	-49,266	-49,330
Loss for the period	-4,574	-2,232	-16,127
Total equity	14,609	33,140	19,184
Accounts payable	1,685	3,154	2,415
Other current liabilities	15,159	868	8,898
Accrued expenses and prepaid income	4,991	5,102	5,047
Total current liabilities	21,835	9,124	16,360
TOTAL STOCKHOLDERS' EQUITY & LIABILITIES	36,444	42,264	35,544

CONSOLIDATED CHANGES IN EQUITY

Amounts in KSEK	JAN-MAR 2012	JAN-MAR 2011	JAN-DEC 2011
Capital stock at the beginning of the period	10,280	11,849	11,849
Reduction	-	-9,479	-9,479
New stock issue	-	7,910	7,910
Total equity	10,280	10,280	10,280
Other capital reserves at the beginning of the period	74,361	53,387	53,387
New stock issue	-	15,817	15,817
New stock issue costs	-	-4,325	-4,325
Reduction	-	9,479	9,479
Other capital reserves	-	-	3
Total, other capital reserves	74,361	74,358	74,361
Other equity at the beginning of the period	-65,457	-49,290	-49,290
Benefit, employee stock option	3	23	-40
Loss for the period	-4,574	-2,231	-16,127
Total, other equity	-70,028	-51,498	-65,457
Total equity at period end	14,609	33,140	19,184

* Other capital reserves have been reduced annually to cover the retained loss. Total other capital reserves before issue costs amount to SEK 486 MSEK.

KEY RATIOS

	JAN-MAR 2012	JAN-MAR 2011	JAN-DEC 2011
Gross margin, %	89	89	89
Loss per stock unit, SEK	-0.01	-0.01	-0.03
Loss per stock unit after dilution, SEK[1]	-0.01	-0.01	-0.03
Equity per stock unit, SEK	0.03	0.06	0.04
Equity per stock unit after dilution, SEK	0.02	0.06	0.03
No. of stock units at the period-end	513,982,256	513,982,256	513,982,256
No of stock units at the period-end after dilution	717,726,550	514,632,779	717,876,640
Average no. of stock units during the period	513,982,256	316,235,918	448,066,810
Average no. of stock units during period after dilution	717,826,610	317,318,944	614,974,956
Cash flow per stock unit, SEK	0.00	0.03	0.00
Operating margin, %	NEG	NEG	NEG
Return on equity, %	NEG	NEG	NEG
Return on capital employed, %	NEG	NEG	NEG
Return on capital, %	NEG	NEG	NEG
Equity/assets ratio, %	46	78	54

[1)] The impact of dilution has not been reported in those cases where dilution would have resulted in an improvement in the key ratios.

CONSOLIDATED STATEMENT OF CASH FLOWS

Amounts in KSEK	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
OPERATING ACTIVITIES			
Net loss after financial items	-4,664	-2,293	-16,522
Adjustment for items not affecting cash flow	290	303	976
Cash flow from operating activities before changes in working capital	-4,374	-1,990	-15,546
CASH FLOW FROM CHANGES IN WORKING CAPITAL			
Changes in inventories etc.	78	-891	-574
Changes in receivables	1,169	-3,837	-9,378
Changes in liabilities	761	868	6,322
Cash flow from operating activities	-2,366	-5,850	-19,176
INVESTMENT ACTIVITIES			
Acquisition of intangible non-current assets	-	-	-819
Acquisition of tangible non-current assets	-	-	-
Sale of tangible non-current assets	-	-	-
Cash flow from investment activities	0	0	-819
FINANCING ACTIVITIES			
Loan	-	-	-
New stock issue	-	19,405	19,405
Cash flow from financing activities	0	19,405	19,405
Cash flow for the period	-2,366	13,555	-591
Cash and cash equivalents at beginning of the period	10,386	11,042	11,042
Transaction of foreign cash	-5	-55	-65
Cash and cash equivalents at end of the period	8,015	24,542	10,386

PARENT COMPANY INCOME STATEMENTS

Amounts in KSEK

	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
Net sales	2,122	8,188	18,414
Cost of goods and services sold	-324	-1,108	-3 310
Gross profit	1,798	7,080	15,104
Other income	-	-	601
Research and development costs (1,2)	-1,437	-1,509	-7,237
Selling costs	-1,711	-975	-7,700
Administrative costs	-2,518	-2,149	-6,353
Other costs	-194	-247	-1,191
Operating profit/loss	-4,062	2,200	-6,776
Interest income and other financial income	54	71	532
Interest expense and other financial expense	-12	-44	-131
Reversal/impairment of receivable, subsidiary	-1,154	84	-13,451
Net financial items	-1,112	111	-13,050
Profit/loss after financial items	-5,174	2,311	-19,826
Tax	-	-	-
Loss for the period*	-5,174	2,311	-19,826

* Equals total comprehensive income

The statements include depreciations and impairment of tangible assets and intangible non-current assets as shown in the following table:

Amounts in KSEK	JAN-MAR 2013	JAN-MAR 2012	JAN-DEC 2012
(1) Capitalized R&D costs	30	30	120
(2) Patents and brand names	22	38	128
Sales rights	66	-	132
Machinery and equipment	8	21	85
Total depriceation	126	89	465

PARENT COMPANY STATEMENTS OF FINANCIAL POSITION

Amounts in KSEK

ASSETS	3/31/2013	3/31/2012	12/31/2012
Capitalized product development costs	290	410	320
Total intangible non-current assets	99	211	121
Total tangible non-current assets	2,435	-	2,501
	2,824	621	2,942
Machinery and equipment	21	93	29
Total tangible non-current assets	21	93	29
Stock and participation in subsidiaries	110	10	110
Receivables from subsidiaries	8,328	14,124	9,483
Total financial non-current assets	8,438	14,134	9,593
Total non-current assets	11,283	14,848	12,564
Raw materials, semi-finished and finished goods	3,108	3,434	2,995
Total inventories etc.	3,108	3,434	2,995
Accounts receivable	909	1,132	756
Receivables from subsidiary	4,287	8,824	3,635
Other receivables	14,504	4,584	12,758
Prepaid expenses and accrued income	3 439	3,119	1,408
otal current receivables	23,139	17,119	18,557
Cash and bank accounts	7,006	23,489	9,399
Total current assets	33,253	44,042	30 951
TOTAL ASSETS	44,536	58,890	43,515

STOCKHOLDERS' EQUITY & LIABILITIES			
Total equity	23,651	51,021	28,825
Provisions	-	-	-
Accounts payable	1,677	3,121	2,407
Current interest-bearing liabilities	680	-	-
Other current liabilities	15,118	868	8,778
Accrued expenses and prepaid income	3,410	3 880	3,505
Total current liabilities	20,885	7,869	14,690
TOTAL STOCKHOLDERS' EQUITY & LIABILITIES	44,536	58,890	43,515

The Board of Directors and the CEO certify that this Report provides a true and fair overview of the Parent Company's and the Group's operations, financial position and results and presents the material risks and uncertainty factors facing the Parent Company and the companies that form part of the Group.

Gothenburg May 30, 2013
Artimplant AB (publ)

John Arnold Board Member	Anders Cedronius Chairman of the Board	Rickard Brånemark Board Member
Håkan Johansson Board Member	Lars Peterson Board Member	Kjell Thörnbring CEO

This report has not been reviewed by the Company's auditors

This information is information which Artimplant is required to publish pursuant to the Swedish Financial Instruments Act and/or the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. The information was published on May 30, 2013 at 2.30 pm (CET).

HISTORY

1986 – 1996 - A medical need is identified and the development of a new biomaterial commences. During subsequent years, material, product and production development takes place and the technology is verified through preclinical trials.

1997 - The Company acquires a Swedish patent for Artelon® hydrolyzable fiber polymers for use in temporary implants. The Company is floated on the Stockholm Stock Exchange. The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.

1998 - The Company acquires Gothenburg Medical Center, a clinic specializing in sports-related injuries.

1999 - Pilot studies in the treatment of damaged thumb ligament and thumb base osteoarthritis are initiated. Artimplant's first multicenter trial in ACL reconstruction begins. Artimplant begins cooperation with Mölnlycke Health Care AB in the field of wound care.

2000 - The first multicenter trial in ACL reconstruction is concluded. The second multicenter ACL reconstruction trial begins. Artimplant's Artelon® patent is approved in the USA and Europe. The marketing organization is expanded.

2001 - Artimplant's quality assurance system is certified by Lloyds Register Quality Assurance. Artimplant's first product, the Artelon® Augmentation Device ACL is granted CE-certification and can now be marketed in Europe. The task of building up the Company's own marketing and sales organization ceased during the autumn. Products and material technology will be commercialized through the granting of licenses to leading companies with a global presence.

2002 - Agreement on wound care signed with Mölnlycke Health Care AB. An extensive restructuring program is commenced to reduce the Company's cost base.

2003 - The Company signs an agreement with Atlantech for sales in the UK of its Artelon® Augmentation Device ACL. Artimplant's Artelon® CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing in Europe. Artelon® Surgical Suture is given clearance by the FDA for sales on the American market. The subsidiary Gothenburg Medical Center is sold.

2004 - Artelon® CMC Spacer receives clearance for marketing from the FDA for sales on the US market. Licensing agreements signed with Small Bone Innovations. A licensing agreement is signed with Biomet Inc. for the production of SportMesh™. Cooperation with Atlantech for the sale of Artelon® Augmentation Device ACL is concluded. Cooperation between Artimplant and Mölnlycke Health Care within wound care is concluded.

2005 - Four new licensing and development agreements are signed with Small Bone Innovations. A distribution agreement for Artelon® Surgical Suture in North America is signed with ArthroCare. Artelon® implant for reinforcing rotator cuffs is cleared for marketing in Europe. Office opened in the United States.

2006 - The Company receives clearance for marketing by the FDA for the sale of the SportMesh™ rotator cuff implant in the USA. Four new Spacer products for the treatment of osteoarthritis in the hand and foot are granted clearance for marketing in Europe. The product Artelon® Augmentation Device ACL is discontinued. Sales of Artelon® CMC Spacer to end-customers increase significantly.

2007 - The Company's sales increase markedly and cash flow improves considerably. The FDA grants clearance to market Artelon® Tissue Reinforcement for soft tissue reinforcement in several new indications in the USA. Two new Spacer products for osteoarthritis in the hand are granted clearance by the FDA for marketing in the USA.

2008 - Sales of Artelon® Tissue Reinforcement increase significantly whilst there is a lack of growth in sales of Artelon® Spacer. Artimplant is initiating new development projects for the treatment of knee joint osteoarthritis and osteoarthritis in the facet joint in the spine. Agreement signed with BioMedtrix regarding the distribution in the USA of Artelon® CCL for cruciate ligament reconstruction in dogs.

2009 – Sales have doubled and product sales to end-customers and distributors have multiplied, increasing its share of total sales to 37% (15). The agreement with Small Bone Innovations was renegotiated, making it non-exclusive from 2009. All patients enrolled for the American post-market study of Artelon® Tissue Reinforcement for the treatment of patients with tears in the rotator cuff tendons. The first patients are included in a clinical study for the treatment of osteoarthritis in the facet joint in the spine with an Artelon® implant. Product design and procedure are developed further for Artelon® CCL. The first dogs in a prospective investigation in the USA underwent cruciate ligament reconstruction using Artelon® CCL

2010 - Own sales have doubled and account for 61% (37) of total product sales whilst license revenue has halved. Artimplant's strategy is market oriented with a focus on the strategically important USA market and Artelon® Tissue Reinforcement. Four product specialists are employed in the USA and costs not related directly to marketing and sales are reduced in Sweden. The American post-market study on Artelon® Tissue Reinforcement for the treatment of the rotator cuff in the shoulder is concluded.

2011 - In the USA, a new marketing and sales initiative commenced with the recruitment of a person to head the subsidiary Artimplant USA Inc., which also acquires a number of new co-workers. Administration and market support are brought together at Artimplant's newly opened office in Denver to create considerably better conditions for building up relationships with agents and customers. Own sales continue to increase, both in absolute numbers and as a proportion of total product sales, albeit from low levels.

2012 - With effect from January, Artimplant takes over the sale of the Spacer product group from the former licensee Small Bone Innovations. The agreement with the Nordic distributor was terminated on January 1. On April 1, the agreement with the licensee Biomet was terminated with the result that all sales take place on the company's own auspices.

Artimplant AB, Hulda Mellgrens Gata 5, SE-421 32 Västra Frölunda, Sweden
Phone +46 31 746 56 00, Fax +46 31 746 56 60, www.artimplant.com

Artimplant
Degradable Materials for Optimal Tissue Repair